FGF23、Klotho在CKD患者心血管疾病中的作用

发布时间：2018-03-01 10:52

本文关键词： FGF23 Klotho CKD CVD　出处：《重庆医科大学》2017年硕士论文　论文类型：学位论文

【摘要】：慢性肾脏病(Chronic kidney diease,CKD)患者由于存在骨-矿物质代谢紊乱(Mineral Bone Disorder,MDB)而使其面临高心血管疾病(Cardiovascular disease,CVD)发病率和死亡风险,但这些高风险并不能用传统的CVD危险因素来解释。深入了解终末期肾脏病(End-stage renal disease,ESRD)患者CVD危险因素及其与左心室肥厚(Left ventricular hyoertrophy,LVH)、心力衰竭、房颤、血管钙化等心血管事件发病机制的关系,可在诊断和治疗由于MBD导致的心血管疾病方面带来很大帮助,从而ESRD患者的生存率。新近的药物治疗方法虽然可使ESRD患者在心血管并发症方面有一定的临床获益,但仍然存在争议。该综述将讨论有关成纤维生长因子23(Fibroblast growth factor23,FGF23)、Klotho蛋白(Klotho protein,Klotho)的基础和临床研究,并阐述其在CKD患者LVH、心力衰竭、房颤、血管钙化等方面的作用、发病机制及治疗。
[Abstract]:Patients with chronic kidney disease (Chronic kidney disease) are exposed to high incidence and death risk of cardiovascular disease due to the presence of bone mineral metabolism disorder mineral Bone disorder (MDBs). But these high risk factors can not be explained by traditional CVD risk factors. To understand the risk factors of CVD in patients with End-stage renal disease and its association with left ventricular hypertrophy, left ventricular hypertrophy, heart failure, atrial fibrillation, heart failure, atrial fibrillation. The relationship between cardiovascular events such as vascular calcification and other cardiovascular events can be of great help in the diagnosis and treatment of cardiovascular diseases caused by MBD. Therefore, the survival rate of patients with ESRD. Although the recent drug therapy can benefit the patients with ESRD in cardiovascular complications, This review will discuss the basic and clinical studies of fibroblast growth factor 23 FGF23 / Klotho protein Klotho protein Klotho, and its role in LVH, heart failure, atrial fibrillation and vascular calcification in patients with CKD.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R692;R54

【参考文献】